MedPlus Health Services vs Thyrocare Technologies: Share Price, Comparison and Key Differences

MedPlus Health Services MCap Rs 8,412 Cr, PE 39.97x, ROE 11.12%, D/E 0.72. Thyrocare Technologies MCap Rs 9,606 Cr, PE 54.62x, ROE 27.85%, D/E 0.09, Div 2.32%.

MedPlus Health Services vs Thyrocare Technologies is a comparison healthcare services investors look up when evaluating two listed Indian companies in retail pharmacy and diagnostics. MedPlus Health Services, a Hyderabad-based company, is one of India’s largest pharmacy retail chains with 4,000+ stores across South and East India selling branded medicines, OTC products and health supplements. Thyrocare Technologies, a Mumbai-based company (now majority-owned by API Holdings / PharmEasy), is a specialized diagnostic laboratory chain offering thyroid, diabetes, cardiac and other preventive health packages at affordable prices through its extensive collection centre network. Both MedPlus vs Thyrocare serve India’s retail healthcare access market.

This MedPlus Health Services vs Thyrocare Technologies article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.

Reach and Market Position

In this MedPlus Health Services vs Thyrocare Technologies comparison, MedPlus operates 4,000+ pharmacy stores across Andhra Pradesh, Telangana, Tamil Nadu, Karnataka, Maharashtra, Odisha and other states. Market capitalisation is Rs 8,412 Cr.

Click Here – Get Free Investment Predictions

Thyrocare operates 1,200+ collection centres and a central reference laboratory in Mumbai, providing affordable diagnostic tests across India. Market capitalisation is Rs 9,606 Cr.

Key Products and Business Mix

For the MedPlus Health Services vs Thyrocare Technologies product breakdown, MedPlus Health Services: MedPlus earns from branded medicine retail, OTC, health supplements and private label pharmacy products. EPS is Rs 17.52. PE is 39.97x, ROE 11.12 percent, D/E 0.72.

Thyrocare Technologies: Thyrocare earns from diagnostic test packages (Aarogyam preventive health packages), thyroid profiles, HbA1c and other tests. EPS is Rs 11.05. PE is 54.62x, ROE 27.85 percent, D/E 0.09. Div 2.32 percent.

Latest Results and Financial Data

On the MedPlus Health Services vs Thyrocare Technologies results front: MedPlus has a market cap of Rs 8,412 Cr and PE of 39.97x. ROE is 11.12 percent. MedPlus and Thyrocare are near-equal in size (Rs 8,412 Cr vs Rs 9,606 Cr).

Thyrocare has a market cap of Rs 9,606 Cr and PE of 54.62x. ROE is 27.85 percent – significantly higher than MedPlus. Thyrocare pays a dividend yield of 2.32 percent.

Compare MedPlus Health Services and Thyrocare Technologies Fundamentals on the Univest Screener

Stock Performance and Valuation

Investors tracking the MedPlus Health Services vs Thyrocare Technologies comparison should verify current prices on NSE or BSE before trading. The MedPlus Health Services vs Thyrocare Technologies stock data below reflects the latest available figures from Groww and public company filings.

MedPlus vs Thyrocare at current valuations: MedPlus trades at Rs 8,412 Cr market cap, PE 39.97x, ROE 11.12 percent. Thyrocare trades at Rs 9,606 Cr market cap, PE 54.62x, ROE 27.85 percent. Near-equal sizes. Thyrocare has a much higher ROE but is also more expensive on PE.

MedPlus Health Services vs Thyrocare Technologies: Quick Comparison Table

The comparison table below summarises the key metrics side by side.

Conclusion

The MedPlus Health Services vs Thyrocare Technologies comparison above covers reach, products, results and valuation. MedPlus Health Services vs Thyrocare Technologies covers retail pharmacy versus affordable diagnostics – two essential healthcare access businesses. MedPlus is a growing pharmacy retailer in South India. Thyrocare is India’s high-volume diagnostic laboratory leader. MedPlus vs Thyrocare investors should track pharmacy store growth, same-store sales, diagnostic test volumes and the competitive environment from online pharmacy and diagnostics players. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track MedPlus Health Services and Thyrocare Technologies live price and get daily stock recommendations.

Frequently Asked Questions

What does MedPlus Health Services sell?

Ans. MedPlus Health Services sells branded prescription medicines, OTC (over-the-counter) healthcare products, health supplements, personal care and private label pharmaceutical products through its 4,000+ pharmacy stores.

What does Thyrocare Technologies do?

Ans. Thyrocare Technologies provides affordable diagnostic tests at its collection centres and reference laboratory. Its flagship Aarogyam packages offer 50-100+ blood tests at affordable prices, focusing on preventive health screening.

Who owns Thyrocare?

Ans. Thyrocare Technologies is now majority-owned by API Holdings (the parent company of PharmEasy, an online pharmacy platform). PharmEasy acquired Thyrocare in 2021.

What is a preventive health package?

Ans. Preventive health packages (like Thyrocare’s Aarogyam) bundle multiple diagnostic blood tests (thyroid, liver function, kidney function, diabetes, lipid profile, vitamins) into affordable packaged offerings for health screening.

Which is larger, MedPlus or Thyrocare?

Ans. Thyrocare at Rs 9,606 Cr is slightly larger than MedPlus at Rs 8,412 Cr – among the closest-matched pairs in this batch.

Does Thyrocare pay dividends?

Ans. Yes. Thyrocare Technologies pays a dividend yield of approximately 2.32 percent – one of the higher yields in healthcare.

Are MedPlus and Thyrocare in Nifty 50?

Ans. Neither is in Nifty 50. Both are tracked in smaller healthcare indices.